Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + ramucirumab + irinotecan + pembrolizumab + eribulin
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen composed of five distinct anti-cancer agents: - **Docetaxel**: a small molecule chemotherapeutic agent (taxane class) that promotes microtubule stabilization, inhibiting cell division and inducing apoptosis. - **Ramucirumab**: a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), acting as an angiogenesis inhibitor. - **Irinotecan**: a small molecule topoisomerase I inhibitor that induces cytotoxic DNA damage in rapidly dividing cells. - **Pembrolizumab**: a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing anti-tumor immune response. - **Eribulin**: a small molecule microtubule inhibitor, binds β-tubulin, disrupts microtubule growth, and arrests the cell cycle at G2/M, with additional non-mitotic effects including epithelial-to-mesenchymal transition reversal and vascular remodeling[1][2][7]. This combination represents multiple mechanistic classes (cytotoxic chemotherapy, targeted therapy, and immunotherapy), potentially with complementary or synergistic effects against various advanced malignancies.
- Other names
- docetaxel + ramucirumab + irinotecan + pembrolizumab + eribulin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on docetaxel + ramucirumab + irinotecan + pembrolizumab + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + ramucirumab + irinotecan + pembrolizumab + eribulin.